Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eptinezumab

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

Lundbeck gets US approval for migraine drug at heart of Alder takeover

US regulator clears CGRP inhibitor under Vyepti trade name

- PMLiVE

Sanofi completes acquisition of immuno-oncology specialist Synthorx

Synthorx is now fully owned by the French drugmaker

- PMLiVE

Lilly will aim for one $1bn-$5bn deal per quarter in 2020

Company seeks to bolster pipeline with a string of M&A activity

- PMLiVE

Newly-listed BioNTech buys Neon to boost cell therapy assets

German biotech has agreed to pay $67m in the deal

- PMLiVE

Galen completes acquisition of healthcare company POA Pharma

Takeover expands Galen's global reach and product portfolio

- PMLiVE

Gilead promotes Andrew Dickinson to CFO, increased M&A expected

Dickinson helmed company’s acquisition of Kite and partnership with Galapagos

- PMLiVE

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Continues to bulk up its pipeline

- PMLiVE

Lundbeck’s key products shine in Q2 but problems remain

Faces increasing patent losses

- PMLiVE

Roche reveals yet another Spark takeover delay

Are concerns about haemophilia dominance the cause?

- PMLiVE

Lundbeck snaps up Abide Therapeutics for $400m

Also acquires its lead drug for Tourette’s syndrome

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links